Page 27 - CPG - Clinical Practice Guidelines - Management of Cancer Pain

Management of Cancer Pain (Second Edition)
The other four recommended tools were Brief Pain Inventory (BPI),
%3, 6KRUW )RUP 034 DQG 3DLQ 'LVDELOLW\ ,QGH[ +RZHYHU WKHUH ZDV
no mention on the quality of the primary papers used in the review.

5HFRPPHQGDWLRQ
• Accurate and comprehensive assessment should be performed prior
to treatment in all patients with cancer pain.
• Appropriate pain assessment tools* should be used regularly on
patients with cancer pain and documented accordingly.
{ 7KH SUHIHUUHG XQLGLPHQVLRQDO WRROV DUH 9LVXDO $QDORJXH 6FDOH
1XPHULFDO 5DWLQJ 6FDOH 9HUEDO 5DWLQJ 6FDOH DQG )DFHV 3DLQ 6FDOH

*Refer to $SSHQGL[ for Assessment Tools

$VVHVVPHQW WRROV IRU QHXURSDWKLF SDLQ
1HXURSDWKLF SDLQ LV GH¿QHG E\ WKH ,QWHUQDWLRQDO $VVRFLDWLRQ IRU WKH
6WXG\ RI 3DLQ ,$63 DV ³SDLQ FDXVHG E\ D OHVLRQ RU GLVHDVH RI WKH
3
somatosensory nervous system”. It is a frequent consequence of
cancer pain and poses considerable suffering to the patients and their
families.

Neuropathic pain is a notable clinical challenge in relation to diagnosis
and thus can be overlooked in cancer pain. A cross-sectional study
looked into the predictors and common symptoms of neuropathic
cancer pain and showed: 17, level III
• predictors were age <65 years old, disease duration >6 months,
stage IV cancer, history of chemotherapy and moderate-to-severe
cancer pain
• common descriptive symptoms were tingling, electric shock, and
‘pins and needles’

It is important to identify neuropathic pain using appropriate tools.
Two diagnostic studies looked into the accuracy of such tools. The
¿UVW VWXG\ RQ 7KH /HHGV $VVHVVPHQW RI 1HXURSDWKLF 6\PSWRPV DQG
6LJQV /$166 VFDOH FRPSDUHG SDLQ RI SUHGRPLQDQWO\ QHXURSDWKLF
or nociceptive origin in patients with refractory cancer-related pain.
Based on the reference test of clinician assessment, the AUC was 0.96
DQG D VSHFL¿FLW\ RI DW D FXW RII YDOXH RI SRLQWV LQ GHWHFWLQJ
neuropathic pain. 18, level I

In another diagnostic study on neuropathic pain in oncology patients
XVLQJ SDLQ VSHFLDOLVW¶V GLDJQRVLV DV WKH JROG VWDQGDUG WKH ¿QGLQJV
were: 19, level III
• AUC of PainDETECT and Doeleur Neuropathique en 4 (DN4)
were 0.870 (95% CI 0.813 to 0.926) and 0.857 (95% CI 0.799 to
0.914) respectively
9

e-cpg inside text-Cancer pain-25/5/24.indd 9 09/08/2024 12:09 AM